Marché mondial des diagnostics COVID-19 – Tendances et prévisions de l’industrie jusqu’en 2029

 Analyse et taille du marché des diagnostics COVID-19

Les Centers for Disease Control and Prevention (CDC) ont développé deux tests de laboratoire pour identifier le SARS-CoV-2, le virus responsable de la COVID-19. Le CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, qui détecte le SARS-CoV-2 dans des échantillons respiratoires, a été le premier test distribué pour le diagnostic de la COVID-19 et a été lancé en février 2020. En juillet 2020, le CDC a lancé le CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay, qui permet aux laboratoires de santé publique d'effectuer trois tests dans un seul puits de réaction. Le Flu SC2 Multiplex utilise moins de réactifs de test, a un débit plus élevé et fournit des résultats précis pour la présence d'acide nucléique du SARS-CoV-2, de la grippe A et de la grippe B dans un échantillon de patient.

Français Data Bridge Market Research analyse que le marché du diagnostic COVID-19, qui était de 46,76 milliards USD en 2021, devrait atteindre 86,55 milliards USD d'ici 2029, à un TCAC de 8,00 % au cours de la période de prévision 2022 à 2029. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des diagnostics COVID-19  

Market Definition

The novel coronavirus is a single-stranded RNA coronavirus that resembles existing SARS-CoV. As this spreads by close contact with an infected individual and is largely spread through respiratory droplets produced by coughing and sneezing. Coronavirus, which is now a global epidemic, was first discovered in the Chinese area of Wuhan. It is also known as coronavirus illness or COVID-19. RT-PCR, isothermal nucleic acid amplification, antibody detection, and other technologies are utilised in testing kits for the COVID-19 test, which is used to identify the SARS-CoV-2 virus. Serological tests are employed for population surveillance, diagnosis, and the identification of antibodies.

Global COVID-19 Diagnostics Market Dynamics

Drivers

•        Need for test kits in hospitals is a driver

The need for coronavirus test kits has expanded along with the coronavirus's widespread. With the aid of test kits, coronavirus identification has become more crucial than ever in order to control the infection's spread and boost the market expansion. Only specialised labs that are licenced to conduct the tests included in this kit, which are of the serology and molecular types. As the kits are based on techniques including real-time polymerase chain reactions, IgM ELISA tests, and microneutralization assays, samples are taken from the nose, sputum test, blood sample, throat swab, and nasal aspirate for testing. The demand for the industry is growing as a result of the global coronavirus outbreak.  As the number of patients in hospitals is increasing rapidly, the need for test kits in hospitals to diagnose the patients with symptoms is also increasing which is further drive the market growth.

•        Technological advancements in COVID-19 rapid testing

Vendors created a variety of innovative rapid testing kits, including cups, cards, and smart test kits. Saliva samples were employed in painless quick testing kits. Additionally, test kits with quicker findings were released on the market. Rapid testing is preferred over other COVID-19 testing kits as a result of these developments. For instance, Meril Diagnostics, an international medical firm with operations in India, produces the non-prescription CoviFind COVID-19 Rapid Antigen Self-Test, which is available and has received approval from the Indian Council of Medical Research (ICMR) for routine usage in India. The introduction of novel and innovative diagnostic tests, such as immunoenzymatic serological tests, rapid antigen tests, and RT PCR-based molecular tests, is expected to drive industry demand.

Opportunities

• Rising number of COVID-19 patients

With the rapidly increasing number of COVID-19 patients worldwide, healthcare professionals require a consistent supply of diagnostic kits, which is expected to have a significant impact on the COVID-19 diagnostics market from 2022 to 2029. The growing number of suspected cases and the need to ensure that test results are correct which has resulted in an increase in demand for more kits, as well as increased safety concerns and the need to diagnose and isolate infected persons, which are expected to boost market growth.

Restraints/Challenges

• Lack of knowledge regarding COVID-19

Lack of knowledge regarding COVID-19 and its symptoms, ability to increase in certain developing regions among professionals will obstruct the market's growth rate. Time required for result is more than 24 hours which is bit longer and will act as a restraint, and further challenge the growth of the COVID-19 Diagnostics market in the forecast period mentioned above. The increased number of false-positive and false-negative results is one of the main drawbacks of fast testing. A set of COVID-19 test kits contained instances of findings that were both falsely positive and falsely negative. When verified with alternate COVID-19 testing, individuals with COVID-19 symptoms both tested negative and positive. These incidents caused the use of COVID-19 fast test kits to decline in some countries.

This COVID-19 diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the COVID-19 diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the COVID-19 Diagnostics Market

COVID-19 had a positive impact on the market, by finding the sick person and person-to-person transmission, the testing significantly contributes to controlling and mitigating the pandemic. One of the most frequently used COVID-19 tests worldwide is rapid antigen testing. Results from this diagnosis, which quantifies the amount of viral protein, can be obtained in within 15 minutes. However, with time, more people started using fast diagnostics kits, and vendors also started making highly sensitive COVID-19 rapid test kits.

Recent developments

• In July 2021, Abbott launched the PanbioTM COVID-19 antigen self-test in India to expand its quick diagnostics offering to meet screening requirements at home, work, and clinics.
• In March 2021 Roche Diagnostics announced the permission for Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) for the COVID-19 rapid antigen test, which is intended for use by healthcare professionals in point-of-care situations with COVID-19 patients.

Global COVID-19 Diagnostics Market Scope

The COVID-19 diagnostics market is segmented on the basis of test type, product, technology, sample type, setting and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Molecular Assays
• Serologic Immunoassays
• Ancillary Diagnostic Tests

 Product

• Polymerase Chain Reaction Kits
• Point-of-care (POC) tests Kits
• Immunoassay
• Instruments
• Reagent and kits

 Technology

• Polymerase Chain Reaction (PCR)
• Enzyme Linked Immunosorbent Assay (ELISA)
• Lateral Flow Immunoassay (LFIA)
• Others

Sample Type

• Oropharyngeal and Nasopharyngeal Swabs
• Nasal Swabs
• Blood
• Others

 Setting

• Lab based
• Point of Care

 End User

• Hospitals
• Public Health Labs
• Private or Commercial Labs
• Urgent care clinics
• Physician Labs

COVID-19 Diagnostics Market Regional Analysis/Insights

The COVID-19 diagnostics market is analysed and market size insights and trends are provided by country, test type, product, technology, sample type, setting and end user as referenced above.

The countries covered in the COVID-19 diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the COVID-19 diagnostics market due to the well-established healthcare system and the presence of numerous existing pharma companies in this particular region.

L'Asie-Pacifique devrait connaître le taux de croissance le plus élevé au cours de la période de prévision de 2022 à 2029 en raison de l'augmentation des cas de coronavirus et de la présence de plusieurs acteurs de l'industrie.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.

Croissance de la base installée des infrastructures de santé et pénétration des nouvelles technologies

Le marché du diagnostic COVID-19 vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les équipements en capital, la base installée de différents types de produits pour le marché du diagnostic COVID-19, l'impact de la technologie à l'aide de courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché du diagnostic COVID-19. Les données sont disponibles pour la période historique 2010-2020.

Analyse du paysage concurrentiel et des parts de marché des diagnostics COVID-19

Le paysage concurrentiel du marché des diagnostics COVID-19 fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des diagnostics COVID-19.

Certains des principaux acteurs opérant sur le marché du diagnostic COVID-19 sont :

• QIAGEN (Allemagne)
• F.Hoffmann-La Roche SA (Suisse)
• Seegene Inc (Corée du Sud)
• SolGent Co. Ltd (Corée du Sud)
• Curetis (Allemagne)
• KURBO INDUSTRIES LTD. (Japon)
• Devex (États-Unis)
• Thermo Fisher Scientific Inc (États-Unis)
• Mylab Discovery Solutions Pvt. Ltd (Inde)
• Abbott (États-Unis)
• Getein Biotech, Inc (Chine)
• Biomaxima SA (Pologne)
• CTK Biotech, Inc (États-Unis)
• CDC (États-Unis)
• BGI (Chine)
• Luminex Corporation (États-Unis)
• Avellino.com (États-Unis)
• PerkinElmer Inc (États-Unis)
• Danaher (États-Unis)
• Thermo Fisher Scientific Inc. (États-Unis)

SKU-55939